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Change in access blood flow over time predicts vascular access
thrombosis.
Background. Vascular access thrombosis accounts for at least $1
billion dollars in annual expenses and 25% of hospitalizations for
chronic hemodialysis patients. Low vascular access blood flow
(less than 800 ml/min) has been shown to modestly increase the
relative risk for thrombosis in the subsequent three months. In
this study, it is hypothesized that a time-dependent decrease in
vascular access blood flow may be more predictive of subsequent
thrombosis especially in vascular accesses with flows more than
800 ml/min, since it would indicate the development of a critical
outlet stenosis in the graft.
Methods. Ninety-five accesses in 91 CHD patients were prospec-
tively followed over 18 months. Vascular access blood flow was
measured every six months by the ultrasound dilution technique.
Thrombotic events were recorded during the three study periods.
Results. A total of 34 thrombotic events in 95 accesses were
documented through the total study duration. Accesses that
thrombosed had a 22% decrease in vascular access blood flow
during the first observation period and a further 41% decrease
during the second observation period as compared to 4% drop
and 15% increase during the first and second observation periods,
respectively, for accesses that did not thrombose. There was an
estimated 13.6-fold (95%, confidence interval 2.68 to 69.16)
increase in the relative risk of thrombosis for accesses with more
than 35% decrease in vascular access blood flow compared to
those accesses with no change in blood flow. There was no
statistical difference in the average vascular access blood flow of
all patients over the study period.
Conclusions. Accesses that show a large (.15%) decrement in
vascular access blood flow are associated with a high risk of
thrombosis. Serial measurements of vascular access blood flow
predict access thrombosis.
Vascular access failure represents a leading cause of
morbidity in the chronic hemodialysis (CHD) population,
being responsible for approximately 25% of all hospital
admissions. According to the 1997 U.S. Renal Data System
Report, Medicare paid for 73,000 hospital admissions and
123,000 outpatient procedures for vascular access-related
problems in 1994, with an estimated annual hospital-
related cost approaching $1 billion per year [1]. The high
level of hospitalization is a consequence of unanticipated
thromboses and generally results in surgical or radiological
intervention for removal of the thrombus and repair of the
attendant stenotic lesion.
The most common cause of thrombosis in polytetrafluo-
roethylene (PTFE) grafts is progressive stenosis of the
venous outlet associated with myointimal proliferation [2].
Recent evidence suggests that when combined with thera-
peutic interventions, prospective screening and detection of
dysfunctional hemodialysis accesses may reduce the throm-
bosis rate and improve its long term patency [3–5]. These
findings have led to recommendations for using a series of
indicators that ostensibly detect stenosis at the venous
anastomosis prior to the development of thrombosis. These
indicators include increased “venous” or dialyzer efferent
pressures [6], intra-access pressures at zero dialyzer flow
[7], urea recirculation, unexplained decline in the dose of
dialysis [8, 9] and vascular access blood flow (VABF) [4].
Among these purported indicators, VABF has been
recently shown to be one of the more sensitive measures of
vascular access dysfunction. Access blood flow can be
measured using several techniques including Doppler ul-
trasonography [10–12], magnetic resonance [13] and ultra-
sound dilution [4]. High cost and operator dependence
have limited the utility of magnetic resonance and to some
extent, Doppler ultrasonography. Ultrasound dilution [14]
is a new method that has been shown to reliably measure
VABF and has been extensively validated for this purpose.
In a recent prospective study, our laboratory have shown
that VABF is a useful indicator of subsequent vascular
access thrombosis in PTFE grafts using either Doppler
ultrasound or ultrasound dilution [15]. Specifically, VABF
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less than 800 ml/min was associated with significant in-
crease in risk of thrombosis in the subsequent three
months. In that study, as well as in another preliminary
study [4], the data analysis was restricted to a single time
point measurement of VABF and the subsequent risk of
thrombosis in the following months. Nevertheless, the
increase in the relative risk of thrombosis for VABF less
than 800 ml/min was modest, primarily because a number
of patients with access blood flows greater than 800 ml/min
also thrombosed and a few patients with VABF less than
800 ml/min did not thrombose in the subsequent three
months. In the current study, we hypothesized that in
addition to a low access blood flow, a time-dependent
decline in VABF may also be predictive of the development
of a critical stenosis and a higher thrombosis risk. We
therefore prospectively studied the association between
changes in VABF and subsequent thrombosis by serially
measuring VABF in a cohort of CHD patients with base-
line VABF levels higher than 800 ml/min.
METHODS
Patient characteristics
A total of 91 CHD patients at the Vanderbilt University
Medical Center outpatient dialysis unit were surveyed
initially for the study. At the first measurement of VABF,
27 patients were found have VABF less than 800 ml/min.
Since those accesses are already at high risk for subsequent
thrombosis based on our earlier published study [15], they
were not included in analysis. Demographic characteristics
of the patients are presented in Table 1. In general, the
study group is reflective of the ESRD population in the
United States. All patients were dialyzed with biocompat-
ible membranes (F-60, F-80, F-8; Fresenius, Concord, CA,
USA) three times per week using the volumetric controlled
dialysis delivery system, Fresenius 2008H. Patients were
anticoagulated using heparin with an initial bolus of 75
U/kg and 500 U/hr that was turned off one half hour before
the end of the treatment.
Vascular access characteristics
Ninety-five permanent vascular accesses, either polytet-
rafluoroethylene (PTFE) grafts (76%) that were at least
four weeks old or native arteriovenous fistulas (AVF)
(24%) that were at least 12 weeks old were included in the
study. Baseline characteristics collected for all accesses
studied including type of vascular access (AVF vs. PTFE),
anatomic location (left or right arm, upper or lower arm)
and configuration of PTFE grafts (loop vs. straight) are
shown in Table 2. During this period 58 accesses were
evaluated three times at six months apart, and 27 accesses
were evaluated twice. Four patients had two vascular
accesses evaluated during the total follow-up time of the
study. The remaining 10 accesses developed irreversible
thrombosis after the first measurement of access flow and
thus were not included in the analysis.
Study design
The study was of prospective cohort design over an 18
month period. Vascular access blood flow and recirculation
were measured utilizing the ultrasound dilution technique
(Transonic Systems, Inc., Ithaca, NY, USA) at 24 week
intervals for a total of three consecutive measurements.
This technique has been extensively validated both ex vivo
and in vitro. The measurement was done within the first one
half hour of the dialysis session for each patient at a blood
flow rate of 400 ml/min. For each study period, measure-
ments in all patients were completed within a window
period of two weeks. All patients were then monitored for
thrombosis and then followed for events over the subse-
quent 22 weeks. To be able to document thrombotic events
as accurately as possible, data were obtained from different
sources: (1) scheduling notebook for the operating room,
(2) log book for access malfunction in the acute dialysis
unit, (3) operating room procedure registry, (4) the proce-
dure logbook of the angioplasty suite at the Radiology
Department, (5) obtaining history from patients, (6) Com-
puter Medical Records Data System, and (7) medical
charts. No specific protocol to correct access malfunction
such as angioplasty or surgical revision was in place during
the study period.
Statistical analysis
For univariate analysis, tests of hypothesis concerning
between group comparisons were made using the mixed
effect analysis of variance (ANOVA). For lifetime data
analysis, distributions of times to events were estimated
with the method of Kaplan and Meier. The PHLEV SAS
Table 1. Demographic characteristics of the study population
Gender (M/F) 53%M/47%F
Race 32% White/68% African-American
Age years 57.6 6 11.4
Cause of ESRD 30% Diabetes
46% Hypertension
4% Glomerulonephritis
4% PKDA
16% Unknown
Table 2. Vascular access characteristics
Access type 76% PTFE grafts
24% AVF
Anatomic location of access 44% Left lower arm
27% Left upper arm
13% Right lower arm
16% Right upper arm
Configuration of PTFE 90% Loop
10% Straight
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macro for proportional hazards model analysis with multi-
ple observable vectors for the same subject [16] was used to
adjust the intracorrelation effect for the patients who had
multiple thrombosis. This procedure is a repeated mea-
sures analysis for correlated time to event follow-up out-
come and a set of predictors. The statistical test results
from the PHLEV SAS models were consistent with the
results from the log-rank test. Because of the very small
number of repeated events within the subject, the statisti-
cally consistent results from both methods were not unex-
pected. For multivariate analysis, the Generalized Estimat-
ing Equation (GEE) method for longitudinal data analysis
[17, 18] was used to adjust the intra-correlation effect for
the patients who had multiple thrombotic events. This
procedure is a repeated measures analysis for correlated
dichotomous outcomes (not adjusted for length of follow-
up). All tests of significance were two-sided, and differ-
ences were considered statistically significant when the P
value , 0.05. All data were expressed as means 6 SD. SAS
version 6.12 and SAS PHLEV macro were used for all
analyses.
RESULTS
A total of 34 thrombotic events in 95 accesses were
documented (0.24 events/access/year) through the total
length of the study. Thirty (88%) thrombotic events were
documented in PTFE grafts and 4 (12%) episodes of
thrombosis occurred in AVF. The mean VABF for all
accesses for the 18 months period of follow-up was 1227 6
700 ml/min (range 243 to 4441). When the average blood
flow of all accesses were calculated, there was no numerical
and/or statistical difference in blood flows at the three
observation periods (1243 6 729 ml/min, range 243 to 3867
for the first period of observation, 1185 6 731 ml/min,
range 284 to 4441 during the second period of observation,
and 1253 6 639 ml/min, range 374 to 3340 for the third
period of observation).
The data were further analyzed for comparison between
accesses that subsequently thrombosed versus those that
did not thrombose. During the first period of observation
VABF was 1205 6 277 ml/min for those accesses that
subsequently thrombosed versus 1579 6 703 ml/min for
those that did not thrombose (P , 0.01). Similarly, for the
second period of observation VABF was 910 6 381 ml/min
for the accesses that had thrombotic events versus 1301 6
811 ml/min for those that had no events (P , 0.01). For the
study period III, the VABF was further reduced to 661 6
276 ml/min for the accesses that had thrombotic events.
Those that did not thrombose had a mean VABF equal to
1287 6 638 ml/min (P , 0.05).
Figure 1 represents the percent changes of VABF be-
tween baseline and the subsequent period of observation
for the accesses that thrombosed versus those that did not
thrombose over the ensuing 22 weeks. The accesses that
thrombosed had a 22% decrease in blood flow between the
first period of observation and the second (P , 0.05), and
41% decrease between the second and third periods of
observation (P , 0.05). In contrast, accesses that did not
thrombose had a 4% decrease in VABF between observa-
tion period one to two and a 15% increase between
observation period two to three.
Figure 2 depicts a diagram of the estimated relative risk
ratio for thrombosis by 5% decrements of vascular access
blood flow over time up to 50% decrease in VABF. When
accesses with no decrease in blood flow were considered as
a reference range (relative risk 1.0), there was a highly
significant exponential increase in the risk of thrombosis for
each blood flow decrement of 15% or higher. Specifically,
for accesses with up to a 15% decrease in access blood flow,
the relative risk of subsequent thrombosis within the next
22 weeks is estimated to be 4.4 times higher (95%, confi-
dence interval 1.08 to 18.11) as compared to those accesses
that have no change in blood flow. When access blood flow
decreased by more than 25% the estimated relative risk of
thrombosis increased approximately sevenfold (95%, con-
fidence interval 1.51 to 30.94). The relative risk of throm-
bosis was 35-fold higher (95%, confidence interval 4.67 to
257.57) when access blood flow was reduced by 50%
compared to those with no decrement in VABF.
Since it has been suggested that native fistulas and PTFE
grafts have different thrombosis patterns, that is, lower
thrombosis rates at lower access blood flows in native
fistulas, we analyzed the data after adjusting for access type.
The results showed that based on the decline in access
blood flow, the estimated relative risk of thrombosis was
the same even with adjustment for each access type without
any numerical or statistical difference.
In Figure 3, the Kaplan-Meier plot of the probability of
access survival is displayed for the group of accesses that
had no change in access blood flow, compared to those
Fig. 1. Vascular access blood flow changes between study period I to II
and study period II to III. P , 0.05 thrombosis vs. no thrombosis for each
period of observation, respectively. Symbols are: (f) thrombosis; (M) no
thrombosis.
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accesses who showed a reduction in VABF grouped in
three different percent changes. As can be seen, the
majority of thrombotic events occurred between day 10
through day 90 following the VABF measurements. Spe-
cifically, at day 90 the probability of patency for accesses
with no change in VABF was 92%. When there was a
decrease in VABF of as much as 25%, the probability of
patency at 90 days was 74% (P , 0.05). Likewise, for those
accesses that had a decrease in VABF equal or higher than
40% the predicted patency rate was 33% within this same
90 day interval (P , 0.01).
DISCUSSION
The results of this prospective study demonstrate that a
temporal decrease in hemodialysis vascular access blood
flow, detected through serial measurements, is a powerful
predictor of vascular access thrombosis within the subse-
quent 24 weeks. Even though sequential access blood flow
screening has been recently proposed in the National
Kidney Foundation-Dialysis Outcomes Qualitative Initia-
tive guidelines [19] as the appropriate screening tool for
vascular access failure, to our knowledge this is the first
study to provide evidence in support of this opinion-based
recommendation.
It is important to note that the authors, as well as several
others have reported the importance of absolute values of
VABF as an indicator of subsequent thrombotic events in
hemodialysis patients, especially when VABF is less than
800 ml/min [15, 20, 21]. However, approximately 20% of
accesses with initial blood flows above 1000 ml/min do
thrombose over the following three to six months. The
results of this study strongly suggest that consecutive mea-
surements of VABF is a reliable and more predictive
method for detecting incipient vascular access failure. Our
analysis shows that sequential measurements of VABF
have a much larger predictive power for thrombosis; for
example, the estimated relative risk increases up to 35
times when a 50% decrease in blood flow occurs compared
to accesses with no change in blood flow.
Several studies have demonstrated that stenosis at the
efferent venous anastomosis of the graft accounts for
approximately 70% of thromboses in PTFE grafts [22–24].
Venous stenosis is thought to result from progressive
narrowing of the vessel lumen over time from the process
of myointimal hyperplasia. This results initially in increased
resistance to blood flow at the venous anastomosis site and
as the intimal proliferation becomes critical, a gradual
decrease in intra-access blood flow occurs that predisposes
the access to thrombosis due to stasis. The findings in this
study are in accordance with the concept that continuous
Fig. 2. Relative risk of thrombosis within the
subsequent 12 weeks by changes in access
blood flow at six months intervals measured by
ultrasound dilution. *P , 0.05, **P , 0.01,
***P , 0.001. Reference group (relative risk 5
1) is the first group with no decrease in blood
flow.
Fig. 3. Kaplan-Meier plot of probability of thrombosis free access sur-
vival according to the percent decrease in vascular access blood flow over
a six month interval versus no change in vascular access blood flow.
Symbols are: (continuous line) no change in VABF; (dotted line) up to
25% decrease in VABF; (dashed line) up to 40% decrease in VABF; *P 5
0.02, **P 5 0.001.
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narrowing in the access along with decreasing blood flow
over time is followed by complete occlusion due to throm-
bosis [25].
The importance of this study can be evaluated in the
context of the significant economic and morbidity burdens
that result from those vascular accesses with unexpected or
sudden thrombosis that are generally detected when a
CHD patient presents for dialysis. This often requires a
hospital admission, placement of a temporary catheter for
dialysis, subsequent angiogram of the access and follow up
angioplasty and/or surgical repair or placement of a new
access. Recent evidence suggests that when combined with
therapeutic interventions, prospective screening and detec-
tion of dysfunctional hemodialysis access grafts may im-
prove the long term patency of the access [3, 5]. However,
such studies have been hampered by the lack of predictive
tests with sufficient sensitivity and specificity. This study
suggests that moderate reduction of VABF is associated
with a high likelihood of access thrombosis in the short
term. Thus, the general availability of this test would allow
radiological (angioplasty) and/or surgical intervention be-
fore the onset of thrombosis, leading to significant savings
in hospitalizations, procedure costs and decreased patient
morbidity.
An important issue that has not been clearly delineated
by this study is the optimal frequency of sequential screen-
ing in order to detect the access at risk. In this study where
measurements of vascular access flow were made every six
months, the majority of thrombotic events occurred within
2 to 12 weeks after a measured (.22%) decrease in access
flow. Therefore, at present, with the available methods of
access screening, we propose that monthly or bimonthly
measurements should be performed for optimal detection.
However, further studies will be needed to define the
optimal interval between measurements that provides early
detection of increased risk of thrombosis without generat-
ing high operational costs of detection that, at present, is
not subject to reimbursement. It is also important to note
that the ultrasound dilution technique used in this study,
although easy to learn, requires well-trained personnel and
makes the screening of large patient populations a time
consuming and labor intensive task.
An additional and important finding in this study was
that relationship between the decline in access blood flow
and the estimated relative risk of thrombosis was not
influenced by access type. Thus, the results of this study
suggest that time dependent changes in access flow are as
predictive in native fistulas as in PTFE grafts for subse-
quent thrombosis, at least in this study population. This is
in contrast to the findings based on absolute access blood
flow measurements which suggest that native fistulas may
function well even at access blood flows below 800 ml/min.
This study therefore provides an important new predictor
for increased risk of thrombosis in native fistulas (as well as
PTFE grafts). It should be noted that the number of native
fistulas followed was relatively small in this study and
further studies with larger number of accesses are needed
to confirm this finding.
In summary, this study has prospectively determined that
measurement of VABF plays an important role in the
evaluation and detection of PTFE grafts at higher risk of
thrombosis, not only through the detection of low VABF
but also through serial measurements, by detecting decre-
ments in VABF over time. These tests provide another tool
to diagnose access malfunction and support the possibility
that early detection and timely correction of underlying
problems prior to thrombosis may play a central role in
maintaining patency of the vascular access and delivering
adequate dialysis therapy.
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